ClinicalTrials.gg
CompletedNCT05235568Updated Aug 20, 2024

VALVOSOFT® Pivotal Study

An interventional study of VALVOSFT intervention in Aortic Valve Calcification and Aortic Valve Stenosis, sponsored by Cardiawave SA. Completed at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-08-20.

Sponsored by Cardiawave SA · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The objective of the study is to evaluate the safety and performance of a new non-invasive ultrasound therapy (NIUT) with Valvosoft in the treatment of Calified Aortic Stenosis

02

Conditions studied

  • Aortic Valve Calcification
  • Aortic Valve Stenosis

Keywords

  • Aortic Valve Stenosis
  • Aortic Valve Calcification
  • Aortic Valve
  • Stenosis
  • Ultrasound
  • non invasive
03

In context

Aortic Valve, Calcification of

44 studies on the registry are indexed under Aortic Valve, Calcification of; 15 are open to participants now.

This study's enrollment of 60 is below the median of 100 across 23 interventional studies indexed under Aortic Valve, Calcification of.

Browse Aortic Valve, Calcification of studies →

Lead sponsor

Cardiawave SA is the lead sponsor of 6 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject suffering from severe symptomatic calcific aortic valve stenosis as defined by ESC/EACTS guidelines for the management of valvular heart disease 2021; and
  2. Subject is not recommended by the local HEART Team for immediate TAVR/SAVR; or
  3. Subject who refuses TAVR/SAVR, documented by local HEART Team (not allowed in France); and
  4. Age ≥18 years; and
  5. Subject willing to provide a written prior to participating in the study; and
  6. Subject who can comply with the study follow-up or other study requirements; and
  7. Subject is eligible for the Valvosoft procedure according to Clinical Review Committee (CRC).

Exclusion criteria

Exclusion Criteria:

  1. Subject with severe aortic regurgitation; or
  2. Subject with unstable arrhythmia not controlled by medical treatment; or
  3. Subjects with implanted mechanical valve in any position or bio-prosthetic valve in aortic position; or
  4. Subject has a chest deformity not allowing optimal placement of Valvosoft Applicator and visualization of the aortic valve; or
  5. Cardiogenic shock or other hemodynamic instability; or
  6. ≤30%; or
  7. Subject with mean AVAI \<0,24 cm²/m2; or
  8. History of heart transplant; or
  9. Subject requiring other cardiac surgery procedures (bypass graft surgery, mitral valve procedure, tricuspid valve procedure) within one month after Valvosoft procedure; or
  10. Cardiac imaging evidence of vegetation; or
  11. Acute myocardial infarction (MI) within one month prior to enrolment; or
  12. Valve depth not suitable for NIUT (depth >125mm with respect to the Valvosoft imaging probe); or
  13. Stroke or (TIA) ≤1 month prior to enrollment; or
  14. Subject who is pregnant, or plan to become pregnant during the 12-months study follow-up period; or
  15. Subject who is participating in another research study for which the primary endpoint has not been reached; or
  16. Balloon aortic valvuloplasty (BAV) ≤3 months prior to enrollment; or
  17. Current endocarditis; or
  18. Leukopenia (WBC \<4000 cell/μL), anemia ( \<8 g/dL), thrombocytopenia ( count \<15.000 cell/μL), or history of coagulopathy or hypercoagulable state; or
  19. \< 6 months due to non-cardiac co-morbid conditions; or
  20. Other medical, psychological, or social condition which, in the opinion of the investigator, precludes the subject from study participation; or
  21. Subjects who do not have Social Security and who are under legal restraint; or
  22. Subjects who cannot read or write or are mentally not or partially capable of giving .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Other
    Valvosoft

    Treatment with VALVOSOFT device

    Device: VALVOSFT intervention

Interventions

  • DeviceVALVOSFT intervention

    Treatment of the calcific aorta valve by non-invasive ultrasound therapy

06

What researchers measure

Primary outcomes

  1. Safety endpoint

    Rate of MACE \< 25%

    Time frame: at 30 days post-procedure

  2. Performance endpoint

    Improvement in clinical status assessed by means of a decrease in NHYA functional class

    Time frame: at 30 days post-procedure

Secondary outcomes

  1. Rate of MACE

    Rate of major adverse and cerebral events

    Time frame: peri-procedureal, and at 3-, 6- and 12 months post procedure

  2. All cause mortality

    All cause mortality

    Time frame: 30 days, 3-, 6- and 12-months post procedure

  3. Rate of Stroke

    Rate of stroke (disabling and non-disabling; ischemic and hemorrhagic)

    Time frame: 30 days, 3-, 6- and 12-months post procedure;

  4. AVA change at 30 days

    Change of 10% in of aortic stenosis by means of aortic valve area (AVA) (assessed by the independent echocardiographic Central Core Laboratory) 30 days post procedure compared to baseline

    Time frame: 30 days post procedure

  5. AVA change in severity

    Change in severity of aortic stenosis by means of aortic valve area (AVA) (assessed by the independent echocardiographic Central Core Laboratory) at 6- and 12 months compared to baseline

    Time frame: at 6- and 12 months

  6. NYHA improvement

    Change in clinical status assessed by means of a decrease in NYHA functional class

    Time frame: 3-, 6- and 12-months

  7. Change in 6 minutes walk test

    Change in 6-minutes' walk test

    Time frame: 30 days, 6- and 12 months

  8. Improvement of quality of life by Kansas City Cardiomyopathy Questionnaire (KCCQ)

    Improvement of quality of life by means of KCCQ. KCCQ is a 23-item, self-administered questionnaire

    Time frame: 30 days, 6-, and 12-months

  9. Improvement of quality of life by EQ-5D

    Improvement of quality of life by means of EQ-5D. The EQ-5D descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

    Time frame: 30 days, 6-, and 12-months

07

Study locations

11 sites
  • CHU Lille Insitut Coeur Poumon
    Lille, France
  • Hopital Bichat Claude-Bernard
    Paris, France
  • Hopital Europeen Georges Pompidou
    Paris, France
  • CHU Reims Hopital Robert Debré
    Reims, France
  • CHU Rouen Hopital Charles Nicole
    Rouen, France
  • Clinique Pasteur
    Toulouse, 31076, France
  • Kerckhoff-klinik
    Bad Nauheim, 61231, Germany
  • Marienkrankenhaus
    Hamburg, Germany
  • OLVG
    Amsterdam, 1091 AC, Netherlands
  • Amphia Hospital
    Breda, Netherlands
  • Radboudumc
    Nijmegen, 6525 AG, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Aug 2023, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2022
First posted
Feb 11, 2022
StartActual
Jun 15, 2022
Primary completionActual
Aug 17, 2023
CompletionActual
Jul 24, 2024
Last update
Aug 20, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05235568
Lead sponsor
Cardiawave SA
Collaborators
QbD Clinical
Responsible party
Sponsor
First posted
Feb 11, 2022
Start date
Jun 15, 2022
Primary completion
Aug 17, 2023
Completion
Jul 24, 2024
Last update
Aug 20, 2024

Study contacts

Christian Spaulding, MD, PhD
principal investigator · HEGP, Paris, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion